INO · XBRL financial data

Inovio Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (INO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	0	0*	0	0	0	0*	0	0	0	0*	0	0
Research and development	16	17*	21	23	19	13*	16	15	13	10*	14	11
General and administrative	10	10*	11	10	9	8*	9	9	8	7*	8	8
Total operating expenses	36	27*	31	33	27	20*	25	23	21	17*	22	19
Operating income (loss)	(36)	(27)*	(31)	(33)	(27)	(20)*	(25)	(23)	(21)	(17)*	(22)	(19)
Interest income	2	2*	2	1	1	1*	1	1	1	0*	0	0
Interest expense	0	0*	0	0	0	0*	0	0	0	0*	—	—
Other income (expense)	0	(1)*	(1)	0	(1)	(2)*	(0)	(1)	(2)	0*	(0)	(2)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(34)	(25)*	(30)	(32)	(25)	(19)*	(20)	(24)	(45)	4*	(20)	(6)
Earnings per share, basic‡ USD per share	(1.56)	—	(1.31)	(1.19)	(0.89)	(0.65)*	(0.51)	(0.61)	(0.87)	—	(0.28)	(0.07)
Earnings per share, diluted‡ USD per share	(1.56)	—	(1.31)	(1.19)	(0.89)	(0.65)*	(0.51)	(0.61)	(0.87)	—	(0.28)	(0.07)
Weighted average shares, basic‡ millions of shares	22	—	23	27	28	30*	39	39	52	58*	69	82
Weighted average shares, diluted‡ millions of shares	22	—	23	27	28	30*	39	39	52	58*	69	82

‡ Per-share figures and share counts are adjusted for the 1-for-12.000048000192 stock split (January 2024); filings made before it reported them unadjusted.
† Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 13x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (INO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	19	14	20	34	22	66	40	24	37	44	26	32
Short-term investments	149	131	86	76	63	28	28	23	14	14	11	5
Accounts receivable	—	2	3	2	2	1	1	1	1	0	—	—
Prepaid and other current assets	5	5	4	5	5	3	2	4	3	3	2	3
Total current assets	175	153	112	118	91	98	72	53	55	61	39	40
Property and equipment, net	6	5	5	5	4	4	3	3	3	3	2	2
Right-of-use asset	9	9	9	9	8	8	8	7	7	7	6	6
Goodwill	0	0	—	—	—	—	—	—	—	—	—	—
Total assets	193	171	129	134	107	113	87	68	69	74	50	49
Total current liabilities	44	43	23	26	23	35	27	32	70	44	38	40
Lease liability, non-current	11	11	11	11	10	9	9	8	7	7	6	5
Total liabilities	55	54	35	37	34	45	36	40	77	50	44	45
Accumulated deficit	(1,598)	(1,623)	(1,653)	(1,686)	(1,711)	(1,730)	(1,750)	(1,773)	(1,819)	(1,815)	(1,835)	(1,841)
Total stockholders' equity	138	117	94	97	74	69	51	29	(8)	24	6	4
Total liabilities and equity	193	171	129	134	107	113	87	68	69	74	50	49
Common shares outstanding (cover page)‡ millions of shares	23	2	26	26	26	37	37	53	54	69	82	103

‡ Per-share figures and share counts are adjusted for the 1-for-12.000048000192 stock split (January 2024); filings made before it reported them unadjusted.
† Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 13x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (INO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(34)	(25)*	(30)	(32)	(25)	(19)*	(20)	(24)	(45)	4*	(20)	(6)
Stock-based compensation	2*	2*	3	2*	1*	1*	1	1*	1*	1*	1	1*
Net cash from operating activities	(29)*	(26)*	(29)	(28)*	(27)*	(20)*	(27)	(21)*	(22)*	(19)*	(22)	(18)*
Purchases of property and equipment	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Net cash from investing activities	(5)*	20*	45	10*	14*	35*	(0)	5*	9*	(0)*	3	6*
Proceeds from issuing common stock	1*	2*	5	17*	1*	13*	1	0*	7*	27*	1	3*
Net cash from financing activities	1*	2*	(11)	33*	1*	29*	1	(0)*	25*	27*	1	17*
Net change in cash	(34)*	(4)*	5	15*	(13)*	44*	(26)	(16)*	12*	8*	(18)	5*

† Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 13x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Inovio Pharmaceuticals	32	0	(18)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Macrogenics	114	33	(41)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2.8	0.4	(5.2)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43	29	(17)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Oncolytics Biotech	4.1	not reported	(8.1)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	16	0.7	(22)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	110	not reported	(4.5)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026
Oramed Pharmaceuticals	15	not reported	(0.2)*	41.6M	80.5 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23	not reported	(30)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.